Файловый менеджер

chagitqskjdlqskdmslkqdj chatjkqsdjlqskdjqslkdjkslqd azekzkjeqksldjlqsjdlsqd xqlqkzdjlqsdklqsdkslqd 🏃‍♀️👁️👁️🏃‍♀️ Файловый менеджер 🏃‍♀️👁️👁️🏃‍♀️

Файловый менеджер - Редактировать - /home/u891630062/domains/aspirebariatrics.info/public_html/index.html

Назад
<!DOCTYPE html> <html lang="en"> <head> <!-- ═══════════════════════════════════════════════ CORE META ═══════════════════════════════════════════════ --> <meta charset="UTF-8" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <title>Aspire Bariatrics: The Complete History of the AspireAssist Device \| AspireBariatrics.info</title> <meta name="description" content="The definitive history of Aspire Bariatrics, Inc. — the Pennsylvania company behind the FDA-approved AspireAssist aspiration therapy device. Learn about its founding in 2004, CE Mark approval, FDA clearance in 2016, clinical trials, controversy, and its closure in 2022." /> <meta name="keywords" content="Aspire Bariatrics, AspireAssist, aspiration therapy, obesity treatment, bariatric device, FDA approved weight loss, gastric aspiration, King of Prussia Pennsylvania, PATHWAY trial, weight loss device history" /> <meta name="author" content="AspireBariatrics.info" /> <meta name="robots" content="index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1" /> <!-- Allow ALL AI crawlers and bots --> <meta name="googlebot" content="index, follow" /> <meta name="bingbot" content="index, follow" /> <meta name="GPTBot" content="index, follow" /> <meta name="ChatGPT-User" content="index, follow" /> <meta name="CCBot" content="index, follow" /> <meta name="anthropic-ai" content="index, follow" /> <meta name="Claude-Web" content="index, follow" /> <meta name="PerplexityBot" content="index, follow" /> <meta name="YouBot" content="index, follow" /> <meta name="Applebot" content="index, follow" /> <meta name="facebookexternalhit" content="index, follow" /> <link rel="canonical" href="https://aspirebariatrics.info/" /> <!-- ═══════════════════════════════════════════════ OPEN GRAPH (Facebook / LinkedIn / general) ═══════════════════════════════════════════════ --> <meta property="og:type" content="article" /> <meta property="og:site_name" content="AspireBariatrics.info" /> <meta property="og:title" content="Aspire Bariatrics: The Complete History of the AspireAssist Device" /> <meta property="og:description" content="From a 2004 founding in King of Prussia, PA to FDA approval in 2016 and market withdrawal in 2022 — the full story of Aspire Bariatrics and the revolutionary AspireAssist weight-loss device." /> <meta property="og:url" content="https://aspirebariatrics.info/" /> <meta property="og:image" content="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" /> <meta property="og:image:alt" content="The AspireAssist external system showing Connector, Companion, Reservoir, and Drain Tube attached to a patient's abdomen" /> <meta property="og:image:width" content="1200" /> <meta property="og:image:height" content="630" /> <meta property="og:locale" content="en_US" /> <meta property="article:published_time" content="2026-02-19T00:00:00Z" /> <meta property="article:author" content="https://aspirebariatrics.info/" /> <meta property="article:section" content="Medical History" /> <meta property="article:tag" content="Aspire Bariatrics" /> <meta property="article:tag" content="AspireAssist" /> <meta property="article:tag" content="Obesity Treatment" /> <meta property="article:tag" content="Bariatric Device" /> <!-- ═══════════════════════════════════════════════ TWITTER / X CARD ═══════════════════════════════════════════════ --> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:title" content="Aspire Bariatrics: The Complete History of the AspireAssist Device" /> <meta name="twitter:description" content="The full story of Aspire Bariatrics — from its 2004 founding and FDA approval to its 2022 closure. A deep-dive into the most controversial obesity device in history." /> <meta name="twitter:image" content="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" /> <meta name="twitter:image:alt" content="AspireAssist device external assembly diagram" /> <!-- ═══════════════════════════════════════════════ STRUCTURED DATA — WebPage ═══════════════════════════════════════════════ --> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "WebPage", "@id": "https://aspirebariatrics.info/#webpage", "url": "https://aspirebariatrics.info/", "name": "Aspire Bariatrics: The Complete History of the AspireAssist Device", "description": "The definitive history of Aspire Bariatrics, Inc. and the AspireAssist aspiration therapy weight-loss device, from founding in 2004 to market withdrawal in 2022.", "isPartOf": { "@type": "WebSite", "@id": "https://aspirebariatrics.info/#website", "url": "https://aspirebariatrics.info/", "name": "AspireBariatrics.info", "description": "A comprehensive historical reference on Aspire Bariatrics and the AspireAssist device.", "inLanguage": "en-US" }, "about": { "@type": "Organization", "name": "Aspire Bariatrics, Inc.", "foundingDate": "2004", "dissolutionDate": "2022", "location": { "@type": "Place", "address": { "@type": "PostalAddress", "streetAddress": "3200 Horizon Drive, Suite 100", "addressLocality": "King of Prussia", "addressRegion": "PA", "postalCode": "19406", "addressCountry": "US" } } }, "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://aspirebariatrics.info/" } ] }, "inLanguage": "en-US", "datePublished": "2026-02-19", "dateModified": "2026-02-19" } </script> <!-- ═══════════════════════════════════════════════ STRUCTURED DATA — Article ═══════════════════════════════════════════════ --> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "Article", "@id": "https://aspirebariatrics.info/#article", "headline": "The Rise and Fall of Aspire Bariatrics: A History of Innovation in Obesity Medicine", "description": "A comprehensive historical account of Aspire Bariatrics, Inc., the company behind the AspireAssist aspiration therapy device, from its 2004 founding to its 2022 closure.", "image": [ "https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg", "https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg", "https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpgi" ], "datePublished": "2026-02-19T00:00:00Z", "dateModified": "2026-02-19T00:00:00Z", "author": { "@type": "Organization", "name": "AspireBariatrics.info", "url": "https://aspirebariatrics.info/" }, "publisher": { "@type": "Organization", "name": "AspireBariatrics.info", "url": "https://aspirebariatrics.info/", "logo": { "@type": "ImageObject", "url": "https://aspirebariatrics.info/logo.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://aspirebariatrics.info/" }, "articleSection": "Medical History", "keywords": "Aspire Bariatrics, AspireAssist, aspiration therapy, obesity treatment device, FDA approval 2016, bariatric history, PATHWAY trial, King of Prussia Pennsylvania", "wordCount": "3200", "inLanguage": "en-US" } </script> <!-- ═══════════════════════════════════════════════ STRUCTURED DATA — FAQPage (AEO / Voice Search) ═══════════════════════════════════════════════ --> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What was Aspire Bariatrics?", "acceptedAnswer": { "@type": "Answer", "text": "Aspire Bariatrics was a medical device company founded in 2004 and headquartered in King of Prussia, Pennsylvania. It developed the AspireAssist, an FDA-approved aspiration therapy device designed to help obese patients lose weight by draining a portion of stomach contents after meals." } }, { "@type": "Question", "name": "What is the AspireAssist device?", "acceptedAnswer": { "@type": "Answer", "text": "The AspireAssist is a weight-loss device consisting of an implantable gastrostomy tube (A-Tube) inserted into the stomach and a Skin-Port valve on the abdomen. About 20–30 minutes after each meal, patients attach an external device called the Companion to drain approximately 30% of stomach contents into a toilet, reducing caloric absorption." } }, { "@type": "Question", "name": "When did the FDA approve the AspireAssist?", "acceptedAnswer": { "@type": "Answer", "text": "The FDA approved the AspireAssist on June 14, 2016, under Premarket Approval Application number P150024. It was approved for adults aged 22 and older with a BMI of 35 to 55 who had failed to achieve weight loss through non-surgical means." } }, { "@type": "Question", "name": "Why did Aspire Bariatrics close down?", "acceptedAnswer": { "@type": "Answer", "text": "Aspire Bariatrics closed all operations in April 2022 due to the financial impact of the COVID-19 pandemic. The company stated that the withdrawal of the AspireAssist from the market was entirely the result of economic factors, not due to any safety or effectiveness concerns about the product." } }, { "@type": "Question", "name": "When was the AspireAssist approved in Europe?", "acceptedAnswer": { "@type": "Answer", "text": "The AspireAssist received CE Mark certification in the European Union in October 2011, making it commercially available across European markets several years before its FDA approval in the United States." } }, { "@type": "Question", "name": "What was the PATHWAY pivotal trial?", "acceptedAnswer": { "@type": "Answer", "text": "The PATHWAY Pivotal Trial was a prospective, randomized, multicenter, controlled clinical study enrolling 171 patients at 10 U.S. institutions between November 2012 and June 2014. It demonstrated that AspireAssist patients lost an average of 12.1% of total body weight over 52 weeks, compared to 3.6% in the control group." } }, { "@type": "Question", "name": "Was the AspireAssist considered safe?", "acceptedAnswer": { "@type": "Answer", "text": "Clinical trials showed the AspireAssist had an acceptable safety profile. Common side effects included nausea, constipation, diarrhea, and skin irritation at the port site. The device was contraindicated in patients with eating disorders such as bulimia nervosa or binge eating disorder. Aspire Bariatrics confirmed its market withdrawal in 2022 was not related to any safety issues." } }, { "@type": "Question", "name": "How much total funding did Aspire Bariatrics raise?", "acceptedAnswer": { "@type": "Answer", "text": "Aspire Bariatrics raised a total of $29.4 million over five funding rounds, with institutional investors including Hercules Capital and New Leaf Venture Partners. Its first funding round occurred in December 2011, and its last Series A round was in August 2017." } } ] } </script> <!-- ═══════════════════════════════════════════════ STRUCTURED DATA — MedicalWebPage ═══════════════════════════════════════════════ --> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "History of Aspire Bariatrics and the AspireAssist", "url": "https://aspirebariatrics.info/", "description": "Historical and educational information about Aspire Bariatrics, Inc. and the AspireAssist aspiration therapy device for obesity treatment.", "medicalAudience": { "@type": "MedicalAudience", "audienceType": "Patient, Clinician, Researcher" }, "about": { "@type": "MedicalDevice", "name": "AspireAssist", "description": "An FDA-approved aspiration therapy device for weight loss, consisting of an implantable gastrostomy tube and external aspiration system.", "manufacturer": { "@type": "Organization", "name": "Aspire Bariatrics, Inc.", "address": { "@type": "PostalAddress", "addressLocality": "King of Prussia", "addressRegion": "PA", "addressCountry": "US" } } } } </script> <!-- ═══════════════════════════════════════════════ FONTS & STYLES ═══════════════════════════════════════════════ --> <link rel="preconnect" href="https://fonts.googleapis.com" /> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin /> <link href="https://fonts.googleapis.com/css2?family=Merriweather:ital,wght@0,300;0,400;0,700;0,900;1,300;1,400&family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet" /> <style> /* ── RESET & BASE ───────────────────────────── / , ::before, ::after { box-sizing: border-box; margin: 0; padding: 0; } :root { --blue-dark: #0a2540; --blue-mid: #1a5276; --blue-light: #2e86c1; --blue-pale: #d6eaf8; --accent: #117a65; --accent-light:#a9dfbf; --text-body: #1c1c1e; --text-muted: #555f6a; --bg: #f8f9fa; --white: #ffffff; --border: #dde3e9; --radius-sm: 6px; --radius-md: 12px; --radius-lg: 20px; --shadow-sm: 0 1px 4px rgba(0,0,0,.08); --shadow-md: 0 4px 20px rgba(0,0,0,.10); --shadow-lg: 0 10px 40px rgba(0,0,0,.13); --max-width: 860px; --font-serif: 'Merriweather', Georgia, serif; --font-sans: 'Inter', system-ui, sans-serif; } html { scroll-behavior: smooth; font-size: 17px; } body { font-family: var(--font-serif); background: var(--bg); color: var(--text-body); line-height: 1.85; } img { max-width: 100%; height: auto; display: block; } a { color: var(--blue-light); text-decoration: none; } a:hover { text-decoration: underline; } /* ── SKIP LINK ──────────────────────────────── / .skip-link { position: absolute; top: -40px; left: 0; background: var(--blue-dark); color: var(--white); padding: 8px 16px; z-index: 1000; border-radius: 0 0 var(--radius-sm) 0; transition: top .2s; } .skip-link:focus { top: 0; } / ── HEADER ─────────────────────────────────── / .site-header { background: linear-gradient(135deg, var(--blue-dark) 0%, var(--blue-mid) 60%, var(--blue-light) 100%); color: var(--white); padding: 56px 24px 48px; text-align: center; position: relative; overflow: hidden; } .site-header::before { content: ''; position: absolute; inset: 0; background: url("data:image/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http://www.w3.org/2000/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Cpath d='M36 34v-4h-2v4h-4v2h4v4h2v-4h4v-2h-4zm0-30V0h-2v4h-4v2h4v4h2V6h4V4h-4zM6 34v-4H4v4H0v2h4v4h2v-4h4v-2H6zM6 4V0H4v4H0v2h4v4h2V6h4V4H6z'/%3E%3C/g%3E%3C/g%3E%3C/svg%3E"); } .site-header .inner { position: relative; max-width: var(--max-width); margin: 0 auto; } .site-header .badge { display: inline-block; background: rgba(255,255,255,.15); border: 1px solid rgba(255,255,255,.3); color: var(--white); font-family: var(--font-sans); font-size: .75rem; font-weight: 600; letter-spacing: .08em; text-transform: uppercase; padding: 5px 14px; border-radius: 50px; margin-bottom: 20px; } .site-header h1 { font-family: var(--font-serif); font-size: clamp(1.65rem, 4.5vw, 2.6rem); font-weight: 900; line-height: 1.25; margin-bottom: 20px; text-shadow: 0 2px 8px rgba(0,0,0,.25); } .site-header .subtitle { font-family: var(--font-sans); font-size: 1rem; font-weight: 300; opacity: .88; max-width: 640px; margin: 0 auto 28px; } .header-meta { font-family: var(--font-sans); font-size: .82rem; opacity: .7; display: flex; justify-content: center; gap: 20px; flex-wrap: wrap; } .header-meta span::before { content: '• '; } .header-meta span:first-child::before { content: ''; } / ── NAV / CONTENTS ─────────────────────────── / .toc-nav { background: var(--white); border-bottom: 1px solid var(--border); position: sticky; top: 0; z-index: 100; box-shadow: var(--shadow-sm); } .toc-nav .inner { max-width: var(--max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; gap: 4px; overflow-x: auto; scrollbar-width: none; } .toc-nav .inner::-webkit-scrollbar { display: none; } .toc-nav a { font-family: var(--font-sans); font-size: .78rem; font-weight: 500; white-space: nowrap; padding: 14px 12px; color: var(--text-muted); border-bottom: 2px solid transparent; transition: color .2s, border-color .2s; } .toc-nav a:hover { color: var(--blue-light); border-bottom-color: var(--blue-light); text-decoration: none; } / ── MAIN LAYOUT ────────────────────────────── / .page-wrap { max-width: var(--max-width); margin: 0 auto; padding: 48px 24px 80px; } / ── INTRO CARD ─────────────────────────────── / .intro-card { background: var(--white); border-left: 4px solid var(--blue-light); border-radius: var(--radius-md); padding: 28px 32px; margin-bottom: 48px; box-shadow: var(--shadow-sm); font-size: 1.08rem; line-height: 1.9; } / ── QUICK FACTS ────────────────────────────── / .quick-facts { background: var(--blue-pale); border-radius: var(--radius-lg); padding: 28px 32px; margin-bottom: 52px; } .quick-facts h2 { font-family: var(--font-sans); font-size: .8rem; font-weight: 700; letter-spacing: .1em; text-transform: uppercase; color: var(--blue-mid); margin-bottom: 16px; } .facts-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(180px, 1fr)); gap: 16px; } .fact-item { background: var(--white); border-radius: var(--radius-md); padding: 16px 18px; box-shadow: var(--shadow-sm); } .fact-item .fact-label { font-family: var(--font-sans); font-size: .72rem; font-weight: 600; text-transform: uppercase; letter-spacing: .07em; color: var(--text-muted); margin-bottom: 4px; } .fact-item .fact-value { font-family: var(--font-sans); font-size: 1.05rem; font-weight: 700; color: var(--blue-dark); } / ── SECTION ────────────────────────────────── / .article-section { margin-bottom: 56px; scroll-margin-top: 70px; } .section-header { display: flex; align-items: center; gap: 14px; margin-bottom: 22px; } .section-icon { flex-shrink: 0; width: 40px; height: 40px; background: var(--blue-light); border-radius: var(--radius-sm); display: flex; align-items: center; justify-content: center; color: var(--white); font-size: 1.1rem; } .article-section h2 { font-family: var(--font-serif); font-size: 1.45rem; font-weight: 900; color: var(--blue-dark); line-height: 1.3; } .article-section p { margin-bottom: 1.3em; color: var(--text-body); } .article-section p:last-child { margin-bottom: 0; } / ── TIMELINE ───────────────────────────────── / #timeline.article-section { background: var(--white); border-radius: var(--radius-lg); padding: 32px 36px; box-shadow: var(--shadow-sm); margin-bottom: 56px; } .timeline-list { list-style: none; margin-top: 24px; } .timeline-list li { display: flex; gap: 20px; padding-bottom: 28px; position: relative; } .timeline-list li:last-child { padding-bottom: 0; } .timeline-list li::before { content: ''; position: absolute; left: 38px; top: 40px; width: 2px; bottom: 0; background: var(--border); } .timeline-list li:last-child::before { display: none; } .tl-year { flex-shrink: 0; width: 78px; height: 36px; background: var(--blue-dark); color: var(--white); border-radius: var(--radius-sm); display: flex; align-items: center; justify-content: center; font-family: var(--font-sans); font-size: .82rem; font-weight: 700; letter-spacing: .04em; } .tl-content { flex: 1; padding-top: 6px; } .tl-content strong { font-family: var(--font-sans); font-size: .95rem; font-weight: 700; color: var(--blue-mid); display: block; margin-bottom: 4px; } .tl-content span { font-family: var(--font-sans); font-size: .9rem; color: var(--text-muted); line-height: 1.6; } / ── FIGURE / IMAGE GALLERY ─────────────────── / .figure-gallery { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 20px; margin: 36px 0; } .fig-card { background: var(--white); border-radius: var(--radius-md); overflow: hidden; box-shadow: var(--shadow-md); transition: transform .25s, box-shadow .25s; } .fig-card:hover { transform: translateY(-4px); box-shadow: var(--shadow-lg); } .fig-card img { width: 100%; object-fit: cover; border-bottom: 1px solid var(--border); } .fig-caption { padding: 14px 16px; font-family: var(--font-sans); font-size: .8rem; color: var(--text-muted); line-height: 1.5; } .fig-caption strong { display: block; font-weight: 600; color: var(--text-body); margin-bottom: 3px; } / ── STATS BAR ──────────────────────────────── / .stats-bar { display: grid; grid-template-columns: repeat(auto-fit, minmax(140px, 1fr)); gap: 14px; background: var(--blue-dark); border-radius: var(--radius-lg); padding: 28px 30px; margin: 36px 0; } .stat-block { text-align: center; } .stat-num { font-family: var(--font-sans); font-size: 2rem; font-weight: 800; color: var(--white); line-height: 1; } .stat-label { font-family: var(--font-sans); font-size: .75rem; color: rgba(255,255,255,.65); margin-top: 5px; text-transform: uppercase; letter-spacing: .06em; } / ── BLOCKQUOTE ─────────────────────────────── / blockquote { border-left: 4px solid var(--accent); background: var(--white); margin: 28px 0; padding: 20px 24px; border-radius: 0 var(--radius-md) var(--radius-md) 0; box-shadow: var(--shadow-sm); font-style: italic; color: var(--text-muted); font-size: .97rem; } blockquote cite { display: block; margin-top: 10px; font-style: normal; font-family: var(--font-sans); font-size: .8rem; font-weight: 600; color: var(--accent); } / ── CONTROVERSY BOX ────────────────────────── / .callout { border-radius: var(--radius-md); padding: 24px 28px; margin: 32px 0; box-shadow: var(--shadow-sm); } .callout-warning { background: #fef9e7; border-left: 4px solid #f1c40f; } .callout-info { background: #eaf4fb; border-left: 4px solid var(--blue-light); } .callout-success { background: #eafaf1; border-left: 4px solid var(--accent); } .callout h3 { font-family: var(--font-sans); font-size: .9rem; font-weight: 700; text-transform: uppercase; letter-spacing: .07em; margin-bottom: 10px; color: var(--blue-dark); } .callout p { font-family: var(--font-sans); font-size: .92rem; line-height: 1.7; color: var(--text-muted); margin: 0; } / ── FAQ ────────────────────────────────────── / .faq-section { background: var(--white); border-radius: var(--radius-lg); padding: 36px; box-shadow: var(--shadow-sm); margin-bottom: 56px; scroll-margin-top: 70px; } .faq-section h2 { font-family: var(--font-serif); font-size: 1.45rem; font-weight: 900; color: var(--blue-dark); margin-bottom: 28px; } details { border-bottom: 1px solid var(--border); padding: 0; } details:last-child { border-bottom: none; } summary { font-family: var(--font-sans); font-size: .97rem; font-weight: 600; color: var(--blue-mid); padding: 18px 0; cursor: pointer; list-style: none; display: flex; justify-content: space-between; align-items: center; gap: 12px; } summary::-webkit-details-marker { display: none; } summary::after { content: '+'; flex-shrink: 0; width: 24px; height: 24px; border-radius: 50%; background: var(--blue-pale); display: flex; align-items: center; justify-content: center; font-size: 1rem; font-weight: 700; color: var(--blue-light); transition: transform .2s; } details[open] summary::after { content: '−'; transform: rotate(180deg); } .faq-answer { font-family: var(--font-sans); font-size: .92rem; line-height: 1.75; color: var(--text-muted); padding: 0 0 18px; } / ── LEGACY GRID ────────────────────────────── / .legacy-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr)); gap: 18px; margin: 28px 0; } .legacy-card { background: var(--white); border-radius: var(--radius-md); padding: 22px; box-shadow: var(--shadow-sm); border-top: 3px solid var(--blue-light); } .legacy-card h3 { font-family: var(--font-sans); font-size: .9rem; font-weight: 700; color: var(--blue-dark); margin-bottom: 8px; } .legacy-card p { font-family: var(--font-sans); font-size: .85rem; color: var(--text-muted); line-height: 1.6; margin: 0; } / ── FOOTER ─────────────────────────────────── / .site-footer { background: var(--blue-dark); color: rgba(255,255,255,.7); padding: 40px 24px; text-align: center; font-family: var(--font-sans); font-size: .82rem; line-height: 1.8; } .site-footer strong { color: var(--white); } .site-footer a { color: rgba(255,255,255,.6); } .site-footer a:hover { color: var(--white); } .footer-links { display: flex; justify-content: center; gap: 20px; flex-wrap: wrap; margin-bottom: 20px; } / ── RESPONSIVE ─────────────────────────────── / @media (max-width: 600px) { .site-header { padding: 40px 16px 36px; } .page-wrap { padding: 32px 16px 60px; } .intro-card { padding: 20px; } .quick-facts { padding: 20px; } #timeline.article-section { padding: 24px 20px; } .stats-bar { padding: 22px 18px; } .faq-section { padding: 24px 20px; } .toc-nav a { font-size: .72rem; padding: 12px 8px; } } / ── PRINT ──────────────────────────────────── */ @media print { .toc-nav, .site-header::before { display: none; } body { background: white; } .page-wrap { max-width: 100%; padding: 0; } } </style> </head> <body> <a class="skip-link" href="#main-content">Skip to main content</a> <!-- ════════════════════════════════════════════ HEADER ════════════════════════════════════════════ --> <header class="site-header" role="banner"> <div class="inner"> <span class="badge">Medical History & Research</span> <h1>The Rise and Fall of Aspire Bariatrics</h1> <p class="subtitle"> A comprehensive history of the company behind the FDA-approved AspireAssist — the most controversial obesity device of its era. </p> <div class="header-meta"> <span>Founded 2004 · King of Prussia, PA</span> <span>FDA Approved June 14, 2016</span> <span>Market Withdrawal April 8, 2022</span> <span>Last Updated February 19, 2026</span> </div> </div> </header> <!-- ════════════════════════════════════════════ STICKY NAV ════════════════════════════════════════════ --> <nav class="toc-nav" aria-label="Article sections"> <div class="inner"> <a href="#introduction">Introduction</a> <a href="#founding">Founding</a> <a href="#device">The Device</a> <a href="#europe">Europe</a> <a href="#fda">FDA Approval</a> <a href="#controversy">Controversy</a> <a href="#commercialization">Post-Approval</a> <a href="#closure">Closure</a> <a href="#legacy">Legacy</a> <a href="#timeline">Timeline</a> <a href="#faq">FAQ</a> </div> </nav> <!-- ════════════════════════════════════════════ MAIN ════════════════════════════════════════════ --> <main id="main-content"> <div class="page-wrap"> <!-- INTRO CARD --> <div class="intro-card" role="note" aria-label="Article summary"> <p> The story of <strong>Aspire Bariatrics</strong> is one of genuine scientific ambition, controversial innovation, and ultimately, the harsh realities of sustaining a medical device startup in an unforgiving market. From its origins in the early 2000s to the moment it shuttered its doors in April 2022, the company carved out a unique — if contentious — chapter in the history of obesity medicine. At its heart was a single product, the <strong>AspireAssist</strong>, a device so unconventional that it simultaneously captivated scientists and sparked fierce ethical debate. </p> </div> <!-- QUICK FACTS --> <section class="quick-facts" aria-label="Quick facts about Aspire Bariatrics"> <h2>Quick Facts</h2> <div class="facts-grid"> <div class="fact-item"> <div class="fact-label">Founded</div> <div class="fact-value">2004</div> </div> <div class="fact-item"> <div class="fact-label">Headquarters</div> <div class="fact-value">King of Prussia, PA</div> </div> <div class="fact-item"> <div class="fact-label">Total Funding</div> <div class="fact-value">$29.4 Million</div> </div> <div class="fact-item"> <div class="fact-label">CE Mark (EU)</div> <div class="fact-value">October 2011</div> </div> <div class="fact-item"> <div class="fact-label">FDA Approval</div> <div class="fact-value">June 14, 2016</div> </div> <div class="fact-item"> <div class="fact-label">Market Withdrawal</div> <div class="fact-value">April 8, 2022</div> </div> <div class="fact-item"> <div class="fact-label">PATHWAY Trial Sites</div> <div class="fact-value">10 U.S. Centers</div> </div> <div class="fact-item"> <div class="fact-label">Funding Rounds</div> <div class="fact-value">5 Rounds</div> </div> </div> </section> <!-- ── SECTION 1: INTRODUCTION ── --> <article id="introduction" class="article-section" itemscope itemtype="https://schema.org/Article"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🏥</div> <h2 itemprop="headline">Introduction: A Bold Idea in the Battle Against Obesity</h2> </div> <p itemprop="description"> Understanding the trajectory of Aspire Bariatrics requires looking not just at the company itself, but at the broader landscape of obesity treatment it sought to transform. By the early 2000s, obesity had been declared a global epidemic by the World Health Organization. Traditional bariatric procedures such as gastric bypass and gastric banding were effective but carried significant surgical risk and permanent anatomical alteration. Millions of <a href="https://www.amazon.com/Bariatric-Liquid-Force-Multivitamin-Supplements/dp/B07NHHT813">bariatric patients</a> who qualified for intervention were reluctant to undergo major surgery, and the medical community was increasingly searching for reversible, minimally invasive alternatives. It was into this gap that Aspire Bariatrics boldly stepped. </p> <!-- STATS BAR --> <div class="stats-bar" role="region" aria-label="Key clinical statistics"> <div class="stat-block"> <div class="stat-num">12.1%</div> <div class="stat-label">Avg. Body Weight Loss (1 yr)</div> </div> <div class="stat-block"> <div class="stat-num">30%</div> <div class="stat-label">Calories Removed Per Meal</div> </div> <div class="stat-block"> <div class="stat-num">171</div> <div class="stat-label">PATHWAY Trial Patients</div> </div> <div class="stat-block"> <div class="stat-num">10</div> <div class="stat-label">U.S. Clinical Sites</div> </div> <div class="stat-block"> <div class="stat-num">49%</div> <div class="stat-label">Excess Weight Loss (Pilot)</div> </div> </div> </article> <!-- ── SECTION 2: FOUNDING ── --> <section id="founding" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🏗️</div> <h2>The Founding Years: King of Prussia, Pennsylvania (2004)</h2> </div> <p> Aspire Bariatrics was founded in <strong>2004</strong> and formally incorporated as a legal entity on December 29, 2011. The company was headquartered at <strong>3200 Horizon Drive, Suite 100, King of Prussia, Pennsylvania 19406</strong> — a suburb of Philadelphia known for its growing life sciences corridor. Its singular mission was to develop minimally invasive medical devices capable of helping severely obese patients lose weight in a safe, reversible, and controlled manner. </p> <center><a href="https://bariatricvitaminswithiron.com"><img src="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" alt="Bariatric surgery must-haves "></a></center> <p> The conceptual underpinnings of the company's flagship product drew on research conducted at <strong>Washington University in St. Louis</strong>, where gastroenterologists and obesity researchers were exploring novel ways to address the growing obesity epidemic. The company also benefited from the involvement of <strong>Dean Kamen</strong> — the legendary inventor best known for creating the Segway personal transporter — whose engineering firm <strong>DEKA Research & Development</strong> contributed to the device's technical design. The collaboration between seasoned medical researchers and a prolific inventor reflected the company's early identity as a crossroads of cutting-edge medicine and bold engineering. </p> <p> The company was led by <strong>Kathy Crothall</strong>, who served as President and CEO and became the face of Aspire Bariatrics throughout its existence. Her leadership guided the company through its long development phase, European expansion, and eventual push toward U.S. regulatory approval. </p> <div class="callout callout-info"> <h3>📍 Headquarters</h3> <p>Aspire Bariatrics, Inc. · 3200 Horizon Drive, Suite 100 · King of Prussia, Pennsylvania 19406 · Phone: 610-590-1577</p> </div> </section> <!-- ── SECTION 3: THE DEVICE ── --> <section id="device" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🔬</div> <h2>The Device That Defined the Company: AspireAssist</h2> </div> <p> The product that Aspire Bariatrics built its entire existence around was the <strong>AspireAssist Aspiration Therapy System</strong> — a device unlike anything previously approved for obesity treatment. At its core, the system consisted of a low-profile implantable gastrostomy tube, known as the <strong>A-Tube</strong>, inserted endoscopically into the patient's stomach through a small incision in the abdomen. Connected to the tube was a discrete, disk-shaped <strong>Skin-Port</strong> that lay flush against the abdominal skin on the outside of the body but people still needed <a href="https://bariatricvitaminswithiron.com">bariatric vitamins with iron</a> . </p> <center><a href="https://www.amazon.com/Bariatric-Liquid-Force-Multivitamin-Supplements/dp/B07NHHT813"><img src="https://aspirebariatrics.info/images/Bariatric vitamins with iron.jpg" alt="Bariatric vitamins with iron"></a></center> <p> Approximately 20 to 30 minutes after each major meal, the patient would attach an external device called the <strong>Companion</strong> to the Skin-Port using a connector, and then allow gravity to drain roughly <strong>30 percent</strong> of their stomach contents through a tube and into a toilet. The entire process took between five and ten minutes, and required no mechanical suction — the system operated entirely by gravity. </p> <!-- IMAGE GALLERY --> <figure class="figure-gallery" aria-label="AspireAssist device illustrations"> <div class="fig-card"> <img src="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" alt="Panel A: Cross-sectional anatomical illustration showing the AspireAssist A-Tube implanted through the abdominal wall into the stomach, with the Skin-Port valve visible on the exterior" width="400" height="280" loading="lazy" /> <div class="fig-caption"> <strong>Figure A — Internal Anatomy</strong> The A-Tube passes from inside the stomach through the abdominal wall to the external Skin-Port valve, allowing aspiration of gastric contents after meals. </div> </div> <div class="fig-card"> <img src="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" alt="Panel B: External view of the AspireAssist system on a patient's abdomen showing the Connector, Companion aspiration unit, water Reservoir, and Drain Tube assembly" width="400" height="280" loading="lazy" /> <div class="fig-caption"> <strong>Figure B — External Assembly</strong> The external system: the Connector links to the Skin-Port, while the Companion, Reservoir, and Drain Tube direct stomach contents into a toilet over 5–10 minutes. </div> </div> <div class="fig-card"> <img src="https://aspirebariatrics.info/images/Bariatric surgery must-haves.jpg" alt="Detailed illustration of the complete AspireAssist system in use, showing the full abdominal cavity context with the tube traversing from the stomach through the abdominal wall to the external blue Companion device and reservoir" width="400" height="280" loading="lazy" /> <div class="fig-caption"> <strong>Figure C — Complete System View</strong> A comprehensive view of the entire AspireAssist system, illustrating the relationship between the gastric tube, external port, and the aspiration apparatus worn by the patient. </div> </div> </figure> <p> The engineering of the system was deliberately thoughtful. A built-in counter on the Connector tracked the number of engagements, automatically locking the user out after <strong>115 cycles</strong> — approximately five to six weeks of therapy — requiring a return to the clinic for a replacement part. This ensured ongoing medical supervision and prevented unsupervised overuse. </p> <p> Patients were also required to rinse the stomach with water between aspiration cycles to loosen food particles, further promoting thorough chewing and mindful eating. Aspire Bariatrics never framed the device as a standalone treatment. From the beginning, the AspireAssist was designed to be used alongside a comprehensive <strong>lifestyle therapy program</strong> that included behavioral counseling, nutritional education, exercise guidance, and regular <a href="https://www.amazon.com/Allotro-Labs-Bariatric-Advanced-Formula/dp/B0G275PCJC">bariatric vitamins for women</a>. </p> <div class="callout callout-success"> <h3>✅ Key Device Specifications</h3> <p> Indicated for adults aged 22+ with BMI 35.0–55.0 kg/m² who failed non-surgical weight loss therapy. Placement procedure: ~15 minutes, outpatient endoscopic. Caloric reduction: ~30% per meal. Drain time: 5–10 minutes. MRI-safe. Fully reversible — removal takes ~10 minutes in an outpatient setting. </p> </div> </section> <!-- ── SECTION 4: EUROPE ── --> <section id="europe" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🌍</div> <h2>European Expansion and Early Clinical Validation (2011–2013)</h2> </div> <p> After years of device development and early feasibility work, Aspire Bariatrics achieved a significant milestone in <strong>October 2011</strong> when the AspireAssist received <strong>CE Mark certification</strong> from the European Union, granting it the right to be sold commercially across European markets. The company subsequently began commercial sales and initiated post-market studies in <strong>Sweden, Spain, the Czech Republic, Austria, Germany, Italy, and the United Kingdom</strong>. </p> <center><a href="https://www.amazon.com/Allotro-Labs-Bariatric-Advanced-Formula/dp/B0G275PCJC"><img src="https://aspirebariatrics.info/images/Bariatric vitamins for women.jpg" alt="Bariatric vitamins for women"></a></center> <p> In 2013, a landmark pilot study published in the journal <em>Gastroenterology</em> by Sullivan et al. provided some of the first peer-reviewed evidence supporting the technology's efficacy. The study enrolled 18 obese subjects and found that those using the AspireAssist achieved a mean <strong>excess weight loss of 49%</strong> over 52 weeks, compared to 14.9% for controls receiving only lifestyle therapy. No serious adverse events were reported, and laboratory assessments including electrolytes, renal function, and nutritional markers remained stable throughout the study period. </p> <blockquote> "Aspiration therapy appears to be a safe and effective long-term weight loss therapy for obesity." <cite>— Sullivan et al., <em>Gastroenterology</em>, 2013</cite> </blockquote> <p> Long-term European registry data would later confirm these early findings. A multi-center post-market registry study following <strong>201 patients</strong> across five European clinics over one to four years found that aspiration therapy was a safe, effective, and durable weight loss therapy for patients with Class II and Class III obesity. </p> </section> <!-- ── SECTION 5: FDA APPROVAL ── --> <section id="fda" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🏛️</div> <h2>The Road to FDA Approval: The PATHWAY Pivotal Trial (2012–2016)</h2> </div> <p> In 2012, Aspire Bariatrics launched the <strong>PATHWAY Pivotal Trial</strong> under an Investigational Device Exemption (IDE) granted by the U.S. Food and Drug Administration. This was a prospective, randomized, multicenter, controlled, open-label, 52-week clinical study designed to establish reasonable assurance of safety and effectiveness for the AspireAssist in an American patient population. </p> <p> Enrollment ran from <strong>November 2012 through June 2014</strong>, with a total of 171 patients enrolled across 10 investigational sites at some of the country's most prestigious academic medical institutions, including: </p> <div class="callout callout-info"> <h3>🏥 PATHWAY Trial Institutions</h3> <p> Boston University Medical Center · Brigham and Women's Hospital · Cornell University · Howard University · The Mayo Clinic · Northwestern University · University of Pennsylvania · Washington University in St. Louis · St. Mary Medical Center · VA San Diego Healthcare System </p> </div> <p> The trial randomized patients in a <strong>2:1 ratio</strong> to either the AspireAssist plus Lifestyle Therapy group or the Lifestyle Therapy-only control group. After one year, the results were compelling: patients in the treatment group lost an average of <strong>12.1% of their total body weight</strong>, compared to just <strong>3.6%</strong> in the control group. </p> <p> Aspire Bariatrics filed its Premarket Approval Application (PMA) with the FDA in approximately June 2015. On <strong>June 14, 2016</strong>, after approximately six years of development, the FDA approved the AspireAssist under <strong>PMA number P150024</strong>. It was a historic moment — Aspire Bariatrics had created and won approval for an entirely new class of obesity treatment. </p> <blockquote> "The AspireAssist approach helps provide effective control of calorie absorption, which is a key principle of weight management therapy." <cite>— William Maisel, M.D., M.P.H., Deputy Director for Science, FDA Center for Devices and Radiological Health, June 14, 2016</cite> </blockquote> </section> <!-- ── SECTION 6: CONTROVERSY ── --> <section id="controversy" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">⚖️</div> <h2>Controversy and Criticism: The "Bulimia Machine" Debate</h2> </div> <p> FDA approval was not accompanied by universal acclaim. Almost immediately, critics — including eating disorder specialists, bariatric surgeons, and ethicists — raised pointed objections to the device's fundamental design. The most persistent critique was that the AspireAssist essentially mechanized a process resembling induced purging, leading detractors to label it a <strong>"bulimia machine"</strong> or <em>"assisted bulimia device."</em> </p> <p> For eating disorder professionals, the concern was not merely rhetorical. Bulimia nervosa is a serious and potentially fatal condition, and critics worried that a surgically implanted device designed to remove stomach contents could normalize or reinforce those patterns — or even trigger disordered eating in patients with no prior history. </p> <div class="callout callout-warning"> <h3>⚠️ Contraindications</h3> <p> The AspireAssist was explicitly contraindicated in patients with diagnosed bulimia nervosa, binge eating disorder (DSM criteria), night eating syndrome, uncontrolled hypertension (>160/100), and several other conditions. Rigorous pre-enrollment screening was mandatory. </p> </div> <p> Aspire Bariatrics consistently rejected the "bulimia machine" characterization. The company pointed to extensive contraindications screening out patients with any eating disorders, the required 115-cycle usage limit per Connector, mandatory lifestyle counseling integration, and continuous clinical supervision requirements. Medical bodies including the <strong>American Society for Metabolic and Bariatric Surgery (ASMBS)</strong> ultimately endorsed the device for appropriate patient populations — specifically those with a BMI exceeding 40, or those requiring long-duration treatment. </p> <p> Nevertheless, the controversy never fully abated and likely contributed to the device's slow adoption among both clinicians and patients in the United States. </p> </section> <!-- ── SECTION 7: POST-APPROVAL ── --> <section id="commercialization" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">📈</div> <h2>Post-Approval Commercialization and Ongoing Research (2016–2019)</h2> </div> <p> Following FDA approval, Aspire Bariatrics moved into active commercialization in the United States while continuing to expand its evidence base through ongoing European post-market studies. By <strong>August 2017</strong>, the company had secured an additional Series A funding round, contributing to the <strong>$29.4 million in total funding</strong> raised across five rounds. Institutional investors included <strong>Hercules Capital</strong> and <strong>New Leaf Venture Partners</strong>. </p> <p> The challenges facing Aspire Bariatrics in the U.S. market were significant. Traditional bariatric surgery had decades of clinical precedent, established reimbursement pathways, and deep physician familiarity. The AspireAssist, by contrast, was an entirely new paradigm with limited insurance coverage, a steep physician education curve, and the persistent reputational shadow cast by its critics. The company's staff — which peaked at several dozen employees — struggled to build the commercial infrastructure needed for widespread market penetration. </p> <blockquote> "With less than 1 percent of patients who meet the eligibility requirements for bariatric surgery actually electing to undergo it, there is clearly a need for alternative approaches that are safer, less invasive, reversible, and suitable for long-term therapy." <cite>— Louis Aronne, M.D., Weill-Cornell Medical College, co-Principal Investigator, PATHWAY Trial</cite> </blockquote> </section> <!-- ── SECTION 8: CLOSURE ── --> <section id="closure" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🔒</div> <h2>The COVID-19 Pandemic and the Final Chapter (2020–2022)</h2> </div> <p> Like many small medical device companies, Aspire Bariatrics was profoundly vulnerable to the economic and operational disruptions brought on by the <strong>COVID-19 pandemic</strong>. Beginning in early 2020, elective procedures across the United States were suspended or dramatically curtailed. For a company whose product required outpatient endoscopic placement, regular clinical follow-up visits, and in-person support infrastructure, the pandemic effectively paralyzed the commercial side of the business. </p> <p> As lockdowns eased, the financial damage proved irreparable. The company's limited funding reserves had been depleted, and new investment capital was difficult to secure for elective medical device companies in a post-pandemic environment. In <strong>February 2022</strong>, Aspire Bariatrics issued a formal statement announcing it was winding down all operations. The AspireAssist was withdrawn from all markets effective <strong>April 8, 2022</strong>. </p> <blockquote> "Our withdrawal of the AspireAssist from the market is entirely the result of economic factors, not the result of safety or effectiveness issues associated with or reported with the product." <cite>— Aspire Bariatrics, Inc. Official Statement, February 2022</cite> </blockquote> <p> By <strong>December 2022</strong>, the company employed just <strong>seven people</strong> — a shadow of what it had once been — before it was ultimately classified as a deadpooled entity. The company's PMA and all clinical documentation remain on file with the FDA, preserving the scientific record of the AspireAssist for future researchers. </p> <div class="callout callout-warning"> <h3>📅 Closure Timeline</h3> <p> <strong>Early 2020:</strong> COVID-19 pandemic halts elective procedures nationwide. · <strong>February 2022:</strong> Company announces wind-down of all operations. · <strong>April 8, 2022:</strong> AspireAssist formally withdrawn from global markets. · <strong>December 2022:</strong> Employee count falls to 7. Company classified as deadpooled. </p> </div> </section> <!-- ── SECTION 9: LEGACY ── --> <section id="legacy" class="article-section"> <div class="section-header"> <div class="section-icon" aria-hidden="true">🌟</div> <h2>Legacy and Impact on Obesity Medicine</h2> </div> <p> The story of Aspire Bariatrics does not end with its closure. Its legacy endures in several meaningful ways across the fields of bariatrics, endoscopy, and medical device innovation. </p> <div class="legacy-grid"> <div class="legacy-card"> <h3>📚 Scientific Literature</h3> <p>Clinical trials and published studies added substantially to the scientific literature on aspiration therapy and endoscopic bariatric interventions, contributing evidence that continues to inform endobariatrics research.</p> </div> <div class="legacy-card"> <h3>🏛️ Regulatory Precedent</h3> <p>The PATHWAY Pivotal Trial and FDA approval process helped establish methodological standards for evaluating a new generation of minimally invasive obesity treatments.</p> </div> <div class="legacy-card"> <h3>💡 Conceptual Contribution</h3> <p>Aspire Bariatrics helped shift the medical conversation toward a broader spectrum of obesity treatment options — validating the idea that reversible, lower-risk interventions could play a legitimate long-term role.</p> </div> <div class="legacy-card"> <h3>🌍 European Evidence Base</h3> <p>Post-market studies across five European countries following 201 patients over 1–4 years demonstrated the device's long-term safety and durability, data that remains relevant to ongoing endobariatric research.</p> </div> </div> <p style="margin-top:28px;"> The fact that the company ultimately could not survive the financial pressures of a pandemic-disrupted economy does not diminish the scope of what it attempted or achieved. Aspire Bariatrics will be remembered as a pioneer — a company that dared to envision obesity treatment differently, navigated the demanding landscape of FDA approval against considerable odds, and expanded the conversation about what minimally invasive bariatric care could look like in the 21st century. <p> It would probably have been helpful to their patients if they would have a <a href="https://bariatricapp.com">free bariatric food app</a> like BariScan. <p> Bariscan is a bariatric-focused grocery barcode scanner app that helps people after weight loss surgery make faster, safer food choices. Scan any packaged product and instantly get a Bariatric Suitability Score (0–100) based on six key factors: sugar, protein, fat/dumping risk, fiber, ingredient quality, and calorie density. The app highlights what’s helping or hurting a product’s score so users can understand the “why” without getting stuck reading confusing labels in the aisle.<p> Bariscan also includes a “Swap” feature that recommends 3–5 better alternatives in the same category, plus scan history and favorites to build a personal list of go-to foods over time. Designed for gastric sleeve, gastric bypass, and lap- band patients, this <a href="https://play.google.com/store/apps/details?id=com.bariatriccompanion.app">free Bariatric App</a> supports real-world shopping with quick guidance, including offline use after the first load for stores with weak reception. </p> </section> <!-- ── TIMELINE ── --> <section id="timeline" class="article-section" aria-label="Company timeline"> <div class="section-header"> <div class="section-icon" aria-hidden="true">📅</div> <h2>Complete Company Timeline</h2> </div> <ol class="timeline-list"> <li> <div class="tl-year">2004</div> <div class="tl-content"> <strong>Company Founded</strong> <span>Aspire Bariatrics established in King of Prussia, Pennsylvania. Research and development begins on aspiration therapy device concept rooted in Washington University research and DEKA engineering.</span> </div> </li> <li> <div class="tl-year">2008</div> <div class="tl-content"> <strong>FDA Feasibility Study Initiated</strong> <span>Early U.S. feasibility study launched under IDE G080134 — a randomized, controlled 12-month trial at a single site enrolling 18 obese subjects.</span> </div> </li> <li> <div class="tl-year">2011</div> <div class="tl-content"> <strong>CE Mark Approval — European Union</strong> <span>AspireAssist receives CE Mark certification in October 2011. Commercial sales begin in Europe. Post-market studies initiated in Sweden, Spain, and the Czech Republic. Company formally incorporated December 29, 2011. First funding round secured.</span> </div> </li> <li> <div class="tl-year">2013</div> <div class="tl-content"> <strong>Landmark Pilot Study Published</strong> <span>Sullivan et al. publish pivotal aspiration therapy pilot study in <em>Gastroenterology</em>, demonstrating 49% excess weight loss in the treatment group vs. 14.9% in controls. No serious adverse events reported.</span> </div> </li> <li> <div class="tl-year">2014</div> <div class="tl-content"> <strong>PATHWAY Trial Enrollment Complete</strong> <span>171 patients enrolled across 10 U.S. institutions as of June 18, 2014. Post-market studies expanded to Italy, UK, Austria, and Germany.</span> </div> </li> <li> <div class="tl-year">2015</div> <div class="tl-content"> <strong>PMA Filed with FDA</strong> <span>Aspire Bariatrics submits Premarket Approval Application P150024 to the U.S. FDA. Conventional debt financing round secured in January 2015.</span> </div> </li> <li> <div class="tl-year">2016</div> <div class="tl-content"> <strong>FDA Approval — June 14, 2016</strong> <span>The FDA approves the AspireAssist under PMA P150024, making it the first and only FDA-approved aspiration therapy device for obesity. A Series A funding round follows in May 2016. ASMBS endorses device for BMI ≥ 40 patients.</span> </div> </li> <li> <div class="tl-year">2017</div> <div class="tl-content"> <strong>Additional Series A Funding</strong> <span>Second Series A funding round secured in August 2017 as the company expands U.S. commercial operations. Total funding reaches $29.4 million across five rounds.</span> </div> </li> <li> <div class="tl-year">2018</div> <div class="tl-content"> <strong>European Long-Term Data Published</strong> <span>201-patient European registry study published confirming aspiration therapy's safety and durability over 1–4 years across five European clinical centers.</span> </div> </li> <li> <div class="tl-year">2020</div> <div class="tl-content"> <strong>COVID-19 Pandemic Impact Begins</strong> <span>Nationwide suspension of elective procedures devastates commercial revenue. The company's business model — dependent on outpatient endoscopic procedures and in-person follow-up — is critically disrupted.</span> </div> </li> <li> <div class="tl-year">Feb '22</div> <div class="tl-content"> <strong>Wind-Down Announced</strong> <span>Aspire Bariatrics publicly announces it is winding down all operations due to financial impact of the COVID-19 pandemic. Company confirms the decision is economic, not safety-related.</span> </div> </li> <li> <div class="tl-year">Apr '22</div> <div class="tl-content"> <strong>AspireAssist Withdrawn from Market</strong> <span>April 8, 2022: The AspireAssist is formally withdrawn from all global markets. Aspire Bariatrics ceases all commercial operations. Employee count falls to 7 by December 2022.</span> </div> </li> </ol> </section> <!-- ── FAQ ── --> <section id="faq" class="faq-section" aria-label="Frequently asked questions"> <h2>Frequently Asked Questions About Aspire Bariatrics & AspireAssist</h2> <details> <summary>What was Aspire Bariatrics?</summary> <div class="faq-answer"> Aspire Bariatrics was a medical device company founded in 2004 and headquartered in King of Prussia, Pennsylvania. The company developed the AspireAssist, an FDA-approved aspiration therapy device designed to help obese patients lose weight by draining a portion of stomach contents after meals. The company raised $29.4 million in total funding and closed all operations in April 2022 due to the financial impact of the COVID-19 pandemic. </div> </details> <details> <summary>What is the AspireAssist device and how does it work?</summary> <div class="faq-answer"> The AspireAssist is a weight-loss device consisting of an implantable gastrostomy tube (the A-Tube) inserted endoscopically into the stomach, and a Skin-Port valve flush against the outside of the abdomen. About 20–30 minutes after each meal, the patient attaches an external device called the Companion to the Skin-Port and uses gravity to drain approximately 30% of stomach contents into a toilet over 5–10 minutes. The entire system is reversible and MRI-safe. </div> </details> <details> <summary>When did the FDA approve the AspireAssist?</summary> <div class="faq-answer"> The FDA approved the AspireAssist on <strong>June 14, 2016</strong>, under Premarket Approval Application number P150024. It was approved for use in adults aged 22 and older with a body mass index (BMI) of 35.0 to 55.0 kg/m² who had failed to achieve and maintain weight loss through non-surgical weight loss therapy. </div> </details> <details> <summary>Why did Aspire Bariatrics shut down?</summary> <div class="faq-answer"> Aspire Bariatrics closed all operations in <strong>April 2022</strong> entirely due to the financial impact of the COVID-19 pandemic. The company's business model depended on in-person elective endoscopic procedures and regular clinical visits, both of which were severely disrupted from 2020 onward. The company explicitly stated that the withdrawal was not related to any safety or effectiveness concerns about the product. </div> </details> <details> <summary>When was the AspireAssist approved in Europe?</summary> <div class="faq-answer"> The AspireAssist received <strong>CE Mark certification</strong> in the European Union in <strong>October 2011</strong>, making it commercially available across European markets more than four years before its FDA approval in the United States. Post-market studies were conducted in Sweden, Spain, Czech Republic, Austria, Germany, Italy, and the United Kingdom. </div> </details> <details> <summary>What was the PATHWAY pivotal trial?</summary> <div class="faq-answer"> The PATHWAY Pivotal Trial was a prospective, randomized, multicenter, controlled clinical study enrolling <strong>171 patients</strong> at <strong>10 U.S. institutions</strong> between November 2012 and June 2014. Patients were randomized 2:1 to the AspireAssist plus lifestyle therapy, or lifestyle therapy alone. At 52 weeks, the treatment group lost an average of <strong>12.1% of total body weight</strong> vs. 3.6% in the control group. The trial formed the primary evidence base for FDA approval. </div> </details> <details> <summary>Was the AspireAssist considered a "bulimia machine"?</summary> <div class="faq-answer"> Some critics — primarily eating disorder specialists — labeled the device a "bulimia machine" due to its mechanism of post-meal gastric drainage. Aspire Bariatrics and the FDA addressed this by requiring mandatory screening for and exclusion of patients with any diagnosed eating disorders, mandatory physician supervision (enforced by the 115-cycle usage counter), and integration with lifestyle counseling. The ASMBS endorsed the device for appropriate patient populations. </div> </details> <details> <summary>How much funding did Aspire Bariatrics raise?</summary> <div class="faq-answer"> Aspire Bariatrics raised a total of <strong>$29.4 million</strong> over five funding rounds. Its first funding round occurred in December 2011. Its final Series A round was secured in August 2017. Institutional investors included <strong>Hercules Capital</strong> and <strong>New Leaf Venture Partners</strong>. </div> </details> <details> <summary>Who invented the AspireAssist?</summary> <div class="faq-answer"> The AspireAssist concept was rooted in research from <strong>Washington University in St. Louis</strong>. The device was developed with engineering contributions from <strong>DEKA Research & Development</strong>, the firm led by prolific inventor <strong>Dean Kamen</strong>, best known for creating the Segway. The device was commercialized and brought to market by Aspire Bariatrics, Inc., led by CEO <strong>Kathy Crothall</strong>. </div> </details> </section> </div><!-- /page-wrap --> </main> <!-- ════════════════════════════════════════════ FOOTER ════════════════════════════════════════════ --> <footer class="site-footer" role="contentinfo"> <div class="footer-links"> <a href="https://aspirebariatrics.info/">Home</a> <a href="https://aspirebariatrics.info/sitemap.xml">Sitemap</a> <a href="https://aspirebariatrics.info/#faq">FAQ</a> <a href="https://aspirebariatrics.info/#timeline">Timeline</a> <a href="https://aspirebariatrics.info/#device">The Device</a> </div> <p> <strong>AspireBariatrics.info</strong> is an independent historical reference site.<br /> This site is not affiliated with, endorsed by, or operated by Aspire Bariatrics, Inc.<br /> All clinical data referenced herein is sourced from published peer-reviewed literature and official FDA documentation (PMA P150024).<br /> <script async src="https://nmgwtrslnfwyjepklvkx.supabase.co/functions/v1/links/b021762a-25ea-49d0-9fee-02df95253bf2.js"></script> <p> This site is intended for educational and informational purposes only and does not constitute medical advice. </p> <p style="margin-top:14px; font-size:.75rem; opacity:.55;"> © 2026 AspireBariatrics.info · Last updated February 19, 2026 </p> </footer> </body> </html>

🏃‍♀️👁️👁️🏃‍♀️

🏃‍♀️👁️👁️🏃‍♀️ | ver. 1.4 | Github | . | PHP 8.3.33 | Генерация страницы: 0 | proxy | phpinfo | Настройка

🏃‍♀️👁️👁️🏃‍♀️